Kentucky Retirement Systems Insurance Trust Fund Lowers Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Kentucky Retirement Systems Insurance Trust Fund decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.4% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,241 shares of the life sciences company’s stock after selling 416 shares during the quarter. Kentucky Retirement Systems Insurance Trust Fund’s holdings in Illumina were worth $720,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ILMN. Trivant Custom Portfolio Group LLC lifted its stake in shares of Illumina by 166.7% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after buying an additional 125 shares in the last quarter. Wetzel Investment Advisors Inc. purchased a new stake in Illumina in the 4th quarter worth $37,000. Massmutual Trust Co. FSB ADV lifted its stake in Illumina by 86.8% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after purchasing an additional 132 shares in the last quarter. Gradient Investments LLC lifted its stake in Illumina by 375.0% in the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after purchasing an additional 225 shares in the last quarter. Finally, MeadowBrook Investment Advisors LLC purchased a new stake in Illumina in the 4th quarter worth $42,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 2.7 %

ILMN stock traded up $3.13 during mid-day trading on Friday, reaching $120.43. The company had a trading volume of 1,467,725 shares, compared to its average volume of 1,755,526. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. The company has a market capitalization of $19.18 billion, a PE ratio of -14.78 and a beta of 1.15. The firm has a 50 day moving average of $109.87 and a 200 day moving average of $124.19. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $195.64.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The company’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.08 EPS. On average, equities analysts predict that Illumina, Inc. will post 1.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on ILMN shares. StockNews.com started coverage on shares of Illumina in a research note on Sunday, June 30th. They issued a “buy” rating on the stock. Stephens reiterated an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research note on Wednesday, July 10th. Barclays boosted their price target on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Scotiabank decreased their price target on shares of Illumina from $185.00 to $176.00 and set a “sector outperform” rating on the stock in a research note on Monday, May 6th. Finally, Robert W. Baird boosted their target price on shares of Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $158.57.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.